A Phase 3b, open-label study to evaluate the non-inferiority of the immune response and to evaluate the safety of the RSVPreF3 OA investigational vaccine in adults 18-49 years of age at increased risk of respiratory syncytial virus disease, compared to older adults ≥60 years of age.

Respiratory Syncytial Virus Infections

"• RSV-A neutralizing titers expressed as GMT ratio (RSV-OA over RSV-A-AIR) at 1 month (Day 31) after study intervention administration. • Seroresponse in RSV-A neutralizing titers from Day 1 to Day 31.", "• RSV-B neutralizing titers expressed as GMT ratio (RSV-OA over RSV-A-AIR) at 1 month (Day 31) after study intervention administration. • Seroresponse in RSV-B neutralizing titers from Day 1 to Day 31. "

"• Occurrence of each solicited administration site event with onset within 4 days after dosing • Occurrence of each solicited systemic event with onset within 4 days after study intervention administration • Occurrence of unsolicited AEs within 30 days after study intervention administration • Occurrence of all SAEs (including fatal and related SAEs) and AESIs after study intervention administration (Day 1) up to study end (Month 6). ", "• RSV-A and RSV-B neutralizing titers, at pre-study intervention administration and 1 month and 6 months after study intervention administration. "

No related papers found yet.

Papers published before 2007-09-01 may not appear yet. Historical indexing is in progress.

Germany